Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SSY GroupLJUIF 86 PEG Ratio is 5.30 as of Jul. 27, 2026, which is 263% above its 10-year median of 1.46. GuruFocus rates LJUIF with a GF Score™ of 86/100 and a GF Value™ of $0.51. The stock has 8 warning signs investors should review. Among 350 Drug Manufacturers companies, SSY Group ranks worse than 74.29% on this metric.
PE Ratio without NRI / 5-Year EBITDA Growth Rate*
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, SSY Group's PE Ratio without NRI is 21.19. SSY Group's 5-Year EBITDA growth rate is 4.00%. Therefore, SSY Group's PEG Ratio for today is 5.30.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for SSY Group's PEG Ratio or its related term are showing as below:
LJUIF'
s PEG Ratio Range Over the Past 10 Years
Min: 0.4 Med: 1.46 Max: 5.08
Current: 4
During the past 13 years, SSY Group's highest PEG Ratio was 5.08. The lowest was 0.40. And the median was 1.46.
LJUIF's PEG Ratio is ranked worse than 74.29% of 350
companies
in the Drug Manufacturers industry
Industry Median: 1.73
vs LJUIF: 4.00
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
SSY Group (OTCPK:LJUIF) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
SSY Group PEG Ratio Related Terms
SSY Group PEG Ratio Historical Data
* Premium members only.
The historical data trend for SSY Group's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, SSY Group's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SSY Group PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SSY Group's PEG Ratio distribution charts can be found below:
* The bar in red indicates where SSY Group's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
SSY Group (LJUIF) has a PEG Ratio of 5.30 as of Jul. 27, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on SSY Group and its competitors. This is 263% above median its historical median of 1.46. Over the past decade, SSY Group's PEG Ratio has ranged from 0.40 to 5.08. According to the industry distribution chart, SSY Group ranks #260 out of 350 companies in the Drug Manufacturers industry, placing it in the top 74.3%.
Is SSY Group's PEG Ratio too high?
SSY Group's current PEG Ratio of 5.30 is 263% above median its 10-year median of 1.46. Over the past 10 years, this metric has ranged from a low of 0.40 to a high of 5.08. The Drug Manufacturers industry median PEG Ratio is 1.73. SSY Group's value of 5.30 is 206.4% above this industry median. Based on the distribution chart, SSY Group ranks #260 out of 350 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, SSY Group has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does SSY Group's PEG Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, SSY Group ranks #260 out of 350 companies for PEG Ratio. This places SSY Group in the lower half of its industry. The industry median PEG Ratio is 1.73. SSY Group's value of 5.30 is 206.4% above this benchmark. Historically, SSY Group's own PEG Ratio has ranged from 0.40 to 5.08 over the past decade. While the company's 10-year median is 1.46 vs. the industry median of 1.73, SSY Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.73, based on 350 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SSY Group's current PEG Ratio of 5.30 is 206.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on SSY Group and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SSY Group's current PEG Ratio is 5.30, which is 263% above median its own 10-year median of 1.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SSY Group stock overvalued right now?
SSY Group (LJUIF) has a current PEG Ratio of 5.30. The stock's GF Value™ is $0.51, compared to a current price of $0.40 — trading 21.1% below its estimated fair value. The current PEG Ratio is 5.30, which is 263% above median its 10-year median of 1.46 and 206.4% above the Drug Manufacturers industry median of 1.73. SSY Group's overall GF Score™ is 86/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For SSY Group (LJUIF), the current PEG Ratio is 5.30 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SSY Group (LJUIF) Overvalued in 2026?
Based on GuruFocus' analysis, SSY Group stock appears to be undervalued.
The current stock price of $0.40 is trading 21.1% below its estimated GF Value™ of $0.51.
Key valuation signals for LJUIF:
PEG Ratio: 5.30 (263% above median its 10-year median of 1.46)
GF Value™: $0.51 vs. price of $0.40 (21.1% below fair value)
Industry Position: 206.4% above the Drug Manufacturers median (#260 of 350)
No single metric tells the full story. See the LJUIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SSY Group Ltd is engaged in the research, development, manufacturing, and selling of a wide range of pharmaceutical products, which include finished medicines of mainly intravenous infusion solutions and ampoule injections to hospitals and distributors, bulk pharmaceuticals, and medical materials. The company has two reportable segments, including intravenous infusion solutions and other medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products. The company derives maximum revenue from PRC.
86GF Score
Get the complete analysis for LJUIF
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LJUIF has been successfully added to your 
